FEOPS NV

Their core work

FEops develops computational simulation and planning software for cardiac interventions, particularly transcatheter procedures such as TAVI (Transcatheter Aortic Valve Implantation). Their core product is a pre-operative planning platform that uses patient-specific imaging and in-silico modeling to predict outcomes before surgery, helping clinicians select the right device and approach. The company sits at the intersection of medical imaging, computational cardiology, and clinical decision support — translating complex simulations into tools that directly reduce procedural risk. More recently, they have expanded into distributed computing architectures to support safety-critical healthcare applications.

What they specialise in

How they've shifted over time

FEops began squarely in computational cardiology (2015-2018), participating in research-oriented projects on cardiac tissue modelling, patient-specific imaging, and transcatheter procedure simulation (MUSICARE, TAVIguide, PIC). From 2019 onward, the company shifted toward productization and infrastructure: HEARTguide (€3.2M, SME Phase 2b) represents the commercialization of their planning tool, while TRANSACT signals expansion into the distributed computing and edge architectures needed to deploy such tools in clinical settings. The trajectory is clear — from research contributor building simulation methods to a product company deploying safety-critical clinical software at scale.

FEops is moving from research-stage simulation toward deployable, distributed clinical decision-support products — expect them to seek partners in cloud infrastructure, regulatory science, and clinical validation.

How they like to work

FEops operates primarily as a participant (4 of 6 projects) but has proven ability to lead, coordinating both TAVIguide (SME Phase 1) and HEARTguide (SME Phase 2b) — a classic SME growth pattern through the EU's SME Instrument pipeline. With 71 unique partners across 17 countries, they maintain a broad and diverse network, suggesting they are well-connected in the European medtech and computational medicine ecosystem rather than reliant on a small circle. They are comfortable in both large research consortia (MSCA training networks) and focused innovation actions.

FEops has collaborated with 71 unique partners across 17 countries, indicating a well-developed pan-European network spanning academic medical centers, simulation research groups, and medtech companies. Their Belgian base and cardiology focus likely connect them strongly to Western European clinical and research hubs.

What sets them apart

FEops occupies a rare niche as a dedicated in-silico planning company for cardiac interventions — most competitors in computational cardiology are academic groups or divisions within large medtech firms, not independent SMEs with their own product pipeline. Their progression from SME Phase 1 (TAVIguide) to Phase 2b (HEARTguide, €3.2M) demonstrates validated commercial potential that few medtech simulation startups achieve. For consortium builders, they bring both deep domain expertise in cardiac simulation and practical experience turning EU-funded research into market-ready clinical tools.

Highlights from their portfolio

• HEARTguide
  Their flagship product project (€3.2M, SME Phase 2b) — represents the commercialization of their transcatheter procedure planning platform and accounts for 72% of their total H2020 funding.
• TRANSACT
  Marks a strategic pivot into distributed cyber-physical systems and edge computing, suggesting FEops is building the infrastructure layer to deploy their clinical tools at scale.
• PIC
  A 5-year research project (2017-2022) in personalised in-silico cardiology that likely provided the foundational science behind their commercial products.